EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Research progress in the metabolic reprogramming of hepatocellular carcinoma (Review)

Wenyue Gao, Jing Wang, Yuting Xu, Hongbo Yu, Sitong Yi, Changchuan Bai, Qingwei Cong, Ying Zhu

Molecular Medicine Reports · 24.05.2024 · 30 (1)

DOI: 10.3892/mmr.2024.13255 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Medicine Reports, online erschienen am 24.05.2024. Verfasst von Wenyue Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116000, P.R China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and its morbidity is increasing worldwide due to increasing prevalence. Metabolic reprogramming has been recognized as a hallmark of cancer and serves a role in cancer progression. Glucose, lipids and amino acids are three major components whose altered metabolism can directly affect the energy production of cells, including liver cancer cells. Nutrients and energy are indispensable for the growth and proliferation of cancer cells, thus altering the metabolism of hepatoma cells can inhibit the progression of HCC. The present review summarizes recent studies on tumour regulatory molecules, including numerous noncoding RNAs, oncogenes and tumour suppressors, which regulate the metabolic activities of glucose, lipids and amino acids by targeting key enzymes, signalling pathways or interactions between the two. These regulatory molecules can regulate the rapid proliferation of cancer cells, tumour progression and treatment resistance. It is thought that these tumour regulatory factors may serve as therapeutic targets or valuable biomarkers for HCC, with the potential to mitigate HCC drug resistance. Furthermore, the advantages and disadvantages of metabolic inhibitors as a treatment approach for HCC, as well as possible solutions are discussed, providing insights for developing more effective treatment strategies for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansAnimalsEnergy MetabolismSignal TransductionGene Expression Regulation, NeoplasticGlucoseLipid MetabolismMetabolic Reprogramming

Stichwörter der Autor:innen

hepatocellular carcinomametabolic reprogrammingnoncoding RNAsoncogenestumour suppressors

Substanzen

Glucose

Autor:innen und Institutionen

  • Department of Infectious Diseases, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116000, P.R China.
  • Internal Department of Chinese Medicine, Dalian Hospital of Traditional Chinese Medicine, Dalian, Liaoning 116000, P.R China.

Zitieren

APA

Gao, W., Wang, J., Xu, Y., Yu, H., Yi, S., Bai, C., Cong, Q., & Zhu, Y. (2024). Research progress in the metabolic reprogramming of hepatocellular carcinoma (Review). Molecular Medicine Reports, 30(1). https://doi.org/10.3892/mmr.2024.13255

Vancouver

Gao W, Wang J, Xu Y, Yu H, Yi S, Bai C, et al. Research progress in the metabolic reprogramming of hepatocellular carcinoma (Review). Molecular Medicine Reports. 2024;30(1). doi:10.3892/mmr.2024.13255

BibTeX
@article{Gao2024,
  author = {Gao, Wenyue and Wang, Jing and Xu, Yuting and Yu, Hongbo and Yi, Sitong and Bai, Changchuan and Cong, Qingwei and Zhu, Ying},
  title = {Research progress in the metabolic reprogramming of hepatocellular carcinoma (Review)},
  journal = {Molecular Medicine Reports},
  year = {2024},
  volume = {30},
  number = {1},
  doi = {10.3892/mmr.2024.13255}
}
Kostenlos starten →